News #MSVirtual2020 – New Safety, Efficacy Data on Mavenclad, Rebif and Evobrutinib on Way #MSVirtual2020 – New Safety, Efficacy Data on Mavenclad, Rebif and Evobrutinib on Way by Joana Carvalho, PhD | September 10, 2020 Share this article: Share article via email Copy article link EMD Serono will present new data from programs assessing the efficacy and safety of Mavenclad (cladribine) andĀ Rebif (interferon beta-1a), as well as investigative evobrutinibĀ in treatingĀ relapsing forms of multiple sclerosis (MS) at the MSVirtual2020 meeting. FindingsĀ are part of 54 abstracts being presented by EMD Serono, known as Merck KGaA outside North America, at the Sept. 11ā13 meeting. They include real-world data on Mavenclad, a review of Rebif’s use by pregnant patients and its safety in people with viral respiratory infections, and preclinical and early clinical trial efficacy results on evobrutinib. āThe broad range of research revealed through these data demonstrate our strategic approach to advancing the MS treatment landscape through new medicines and patient-focused research initiatives,ā Luciano Rossetti, global head of Research & Development at EMD Serono, said in a press release. Regarding Mavenclad, the companyās oral, short-course therapy for those with active and relapsing forms of MS, new data comes from the Phase 3 CLARITY trial (NCT00213135) and its extension study (NCT00641537) on the therapyās long-term efficacy at reducing the incidence of cumulative MS relapsesĀ over five years. Findings from a post-hoc analysis of CLARITY investigating the five-year effects of Mavenclad on patientsā disability ā assessed by the Expanded Disability Status Scale (EDSS) ā will also be presented. The company will also present new data from two Phase 4 trials of Mavenclad ā MAGNIFY (NCT03364036) and CLARIFY (NCT03369665) ā including the clinical outcomes of MS patients infected with COVID-19Ā while taking the medication during these trials. Long-term efficacy and real-world data from another Phase 4Ā Mavenclad trial, called CLASSIC MS (NCT03961204), will be presented as part of the late-breaker sessions taking place on Sept. 25ā26. Updated post-approval safety data covering both Mavenclad and Rebif in treating MS, including a look at the risk of respiratory infections of concern during the ongoing pandemic. āMuch of our data provide insights on how Mavenclad and Rebif affect the risk of respiratory viral infections and COVID-19 outcomes in MS patients. These insights will help support clinicians as they make treatment decisions for their patients living with MS,ā Rossetti said. New data will also come from an open-label extension of a Phase 2 trial (NCT02975349) assessing the long-term efficacy of its investigational, oralĀ BTK inhibitor, called evobrutinib, in patients with relapsing forms of MS. EMD Serono will also present findings from a preclinical study of evobrutinibās potential in lowering inflammation in the central nervous system (CNS; composed by the brain and spinal cord), which is thought to be one of the key drivers of MS. Print This Page About the Author Joana Carvalho, PhD Joana holds a bachelorās in biology, a Master of Science in evolutionary and developmental biology, and a PhD in biomedical sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells ā those that make up the lining of blood vessels ā found in the umbilical cord of newborns. In addition to several research fellowships, she was awarded two Erasmus scholarships to conduct part of her studies in France. Tags #MSVirtual2020, Cladribine, CLARITY, EMD Serono, evobrutinib, Mavenclad, Rebif
May 7, 2024 News by Margarida Maia, PhD Wayne State professor wins grant to study oligodendrocytes in MS
May 6, 2024 News by Marisa Wexler, MS Nearly $650k awarded to advance potential remyelination drug IFB-048
May 3, 2024 News by Steve Bryson, PhD Charles River to help FibroBiologics produce 3D cell-based therapiesĀ